id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2001-P-0152-0004,FDA,FDA-2001-P-0152,FDA/CDER to Aspire Pharmaceuticals Inc,Other,LET-Letter,2002-05-15T04:00:00Z,2002,5,,,2008-04-25T02:27:08Z,,0,0,09000064804ddd6a
FDA-2001-P-0152-0003,FDA,FDA-2001-P-0152,FDA,Notice,N-Notice,2002-05-07T04:00:00Z,2002,5,,,2008-04-25T02:27:08Z,,0,0,09000064804ddd67
FDA-2001-P-0152-0002,FDA,FDA-2001-P-0152,FDA/CDER to Aspire Pharmaceuticals Inc,Other,LET-Letter,2002-01-22T05:00:00Z,2002,1,,,2008-04-25T02:27:08Z,,0,0,09000064804ddd65
FDA-2001-P-0152-0001,FDA,FDA-2001-P-0152,FDA/DDM,Other,ACK-Acknowledgement Letter,2001-07-25T04:00:00Z,2001,7,,,2008-04-25T02:27:08Z,,0,0,09000064804ddd42